BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 07/11/19

The first patient has been dosed with BioTime's ( BTX ) new off-the-shelf Thaw-and-Inject formulation of OpRegen using the Orbit Subretinal Delivery System (Orbit SDS) in a Phase 1/2a clinical trial in patients with dry age-related macular degeneration. More news on: BioTime, Inc., Hea...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new Thaw-and-Inject formulat...

BioTime (NYSEMKT: BTX ) is up  8%  after hours following its announcement that it has agreed to sell 2.25M OncoCyte (NYSEMKT: OCX ) shares at $2 per share, yielding gross proceeds of $4.5M. The transaction should close on July 5. More news on: BioTime, Inc., OncoCyte Corporatio...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of the sale of 2,250,000 shares of common stock of OncoCyte Corporation at a price to buyers of $2.00 per share, for gross proceed...

Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue grow...

There are several reasons biotechnology stocks are an investor favorite. One of those reasons is that this is a vast sector. Here, companies great and small develop the next generation of treatments and medical advancements that cover everything from chronic illness to cosmetic enhan...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary. “We’re extremely fo...

Buckeye Partners, L.P. (NYSE: BPL ) +27%  on Q1 earnings . More news on: Buckeye Partners, L.P., Cool Holdings, Inc., Westport Fuel Systems Inc., Stocks on the move, Read more ...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel...

BioTime, Inc. (BTX) Q1 2019 Earnings Conference Call May 09, 2019 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Ed Wirth - Chief Medical Officer Gary Hogge - Senior V...